FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2085752449> ?p ?o ?g. }

• W2085752449 endingPage "1445" @default.
• W2085752449 startingPage "1445" @default.
• W2085752449 abstract "VEGF is a target molecule for peritoneal metastasis and malignant ascites in gastric cancer: prognostic significance of VEGF in ascites and efficacy of anti-VEGF monoclonal antibody Sachio Fushida, Katsunobu Oyama, Jun Kinoshita, Yasumichi Yagi, Kouichi Okamoto, Hidehiro Tajima, Itasu Ninomiya, Takashi Fujimura, Tetsuo OhtaDepartment of Gastroenterological Surgery, Kanazawa University Hospital, Kanazawa, JapanBackground: In gastric cancer, poor prognosis is associated with peritoneal dissemination, which often accompanies malignant ascites. We searched for a target molecule in peritoneal metastasis and investigated its clinical utility as a biomarker.Methods: Biopsy specimens from both primary lesions and peritoneal metastasis, and if possible, malignant ascites, were obtained from 40 patients with gastric cancer. Vascular endothelial growth factor (VEGF) expression was analyzed by immunohistochemical staining and enzyme-linked immunosorbent assay.Results: VEGF expression was seen in 70% of peritoneal samples. Of the 40 patients, 35 had malignant ascites. These 35 patients were divided into two groups: 15 with ascites found beyond the pelvic cavity (large group) and 20 whose ascites were within the pelvic cavity (small group). The two groups did not significantly differ by serum VEGF levels, but ascites VEGF levels in the large group were significantly higher than in the small group (P < 0.0001). Serum VEGF and ascites VEGF levels were highly correlated in the large group (r = 0.686). A high ascites VEGF level was found to be a risk factor for survival (P = 0.045). We include a report of a patient with chemoresistant refractory gastric cancer and symptomatic ascites who obtained 8 months of palliation from systemic bevacizumab.Conclusion: Anti-VEGF therapies are promising, and the ascites VEGF level is an important marker in managing patients with gastric cancer and peritoneal metastasis.Keywords: vascular endothelial growth factor, malignant ascites, peritoneal metastasis, gastric cancer, bevacizumab" @default.
• W2085752449 created "2016-06-24" @default.
• W2085752449 creator A5007365936 @default.
• W2085752449 creator A5011681054 @default.
• W2085752449 creator A5024644803 @default.
• W2085752449 creator A5048730959 @default.
• W2085752449 creator A5056226936 @default.
• W2085752449 creator A5061456550 @default.
• W2085752449 creator A5074701942 @default.
• W2085752449 creator A5081758735 @default.
• W2085752449 creator A5083439802 @default.
• W2085752449 date "2013-10-01" @default.
• W2085752449 modified "2023-10-10" @default.
• W2085752449 title "VEGF is a target molecule for peritoneal metastasis and malignant ascites in gastric cancer: prognostic significance of VEGF in ascites and efficacy of anti-VEGF monoclonal antibody" @default.
• W2085752449 cites W1494416455 @default.
• W2085752449 cites W1542216227 @default.
• W2085752449 cites W173453493 @default.
• W2085752449 cites W1964151408 @default.
• W2085752449 cites W1975099907 @default.
• W2085752449 cites W1983763042 @default.
• W2085752449 cites W1985059602 @default.
• W2085752449 cites W1987653325 @default.
• W2085752449 cites W1994210197 @default.
• W2085752449 cites W1995681132 @default.
• W2085752449 cites W1997294735 @default.
• W2085752449 cites W2013242810 @default.
• W2085752449 cites W2013806881 @default.
• W2085752449 cites W2026203259 @default.
• W2085752449 cites W2028922282 @default.
• W2085752449 cites W2034903741 @default.
• W2085752449 cites W2040843411 @default.
• W2085752449 cites W2042289946 @default.
• W2085752449 cites W2055044954 @default.
• W2085752449 cites W2057440670 @default.
• W2085752449 cites W2061358741 @default.
• W2085752449 cites W2064363496 @default.
• W2085752449 cites W2066370100 @default.
• W2085752449 cites W2068460700 @default.
• W2085752449 cites W2079195167 @default.
• W2085752449 cites W2080881382 @default.
• W2085752449 cites W2083570617 @default.
• W2085752449 cites W2085477268 @default.
• W2085752449 cites W2087911316 @default.
• W2085752449 cites W2107492221 @default.
• W2085752449 cites W2108145145 @default.
• W2085752449 cites W2114739852 @default.
• W2085752449 cites W2122866527 @default.
• W2085752449 cites W2135375037 @default.
• W2085752449 cites W2142874979 @default.
• W2085752449 cites W2152657512 @default.
• W2085752449 cites W2155167083 @default.
• W2085752449 cites W2158118791 @default.
• W2085752449 cites W2171075804 @default.
• W2085752449 cites W2266406082 @default.
• W2085752449 cites W2316550643 @default.
• W2085752449 cites W2395160846 @default.
• W2085752449 doi "https://doi.org/10.2147/ott.s51916" @default.
• W2085752449 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3804591" @default.
• W2085752449 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24204159" @default.
• W2085752449 hasPublicationYear "2013" @default.
• W2085752449 type Work @default.
• W2085752449 sameAs 2085752449 @default.
• W2085752449 citedByCount "35" @default.
• W2085752449 countsByYear W20857524492013 @default.
• W2085752449 countsByYear W20857524492014 @default.
• W2085752449 countsByYear W20857524492015 @default.
• W2085752449 countsByYear W20857524492016 @default.
• W2085752449 countsByYear W20857524492018 @default.
• W2085752449 countsByYear W20857524492019 @default.
• W2085752449 countsByYear W20857524492020 @default.
• W2085752449 countsByYear W20857524492021 @default.
• W2085752449 countsByYear W20857524492022 @default.
• W2085752449 countsByYear W20857524492023 @default.
• W2085752449 crossrefType "journal-article" @default.
• W2085752449 hasAuthorship W2085752449A5007365936 @default.
• W2085752449 hasAuthorship W2085752449A5011681054 @default.
• W2085752449 hasAuthorship W2085752449A5024644803 @default.
• W2085752449 hasAuthorship W2085752449A5048730959 @default.
• W2085752449 hasAuthorship W2085752449A5056226936 @default.
• W2085752449 hasAuthorship W2085752449A5061456550 @default.
• W2085752449 hasAuthorship W2085752449A5074701942 @default.
• W2085752449 hasAuthorship W2085752449A5081758735 @default.
• W2085752449 hasAuthorship W2085752449A5083439802 @default.
• W2085752449 hasBestOaLocation W20857524491 @default.
• W2085752449 hasConcept C121608353 @default.
• W2085752449 hasConcept C126322002 @default.
• W2085752449 hasConcept C141071460 @default.
• W2085752449 hasConcept C142724271 @default.
• W2085752449 hasConcept C167734588 @default.
• W2085752449 hasConcept C204232928 @default.
• W2085752449 hasConcept C2777025900 @default.
• W2085752449 hasConcept C2778536324 @default.
• W2085752449 hasConcept C2779013556 @default.
• W2085752449 hasConcept C2780496750 @default.
• W2085752449 hasConcept C71924100 @default.
• W2085752449 hasConcept C90924648 @default.
• W2085752449 hasConceptScore W2085752449C121608353 @default.
• W2085752449 hasConceptScore W2085752449C126322002 @default.

• next